Deficient glutamate tranport is associated with neurodegeneration in Alzheimer's disease

PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT

Lowry, O. H., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 316,394

Neuropathological stageing of Alzheimer-related changes.

Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123

LIGAND: A versatile computerized approach for characterization of ligand-binding systems

Munson, P. J., & Rodbard, D. (1980) · Analytical Biochemistry · doi:10.1016/0003-2697(80)90515-1 · Cited by 8,373

Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease

Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659

Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment

Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668

Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein

Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516

Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity

DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376

Ionic dependence of glutamate neurotoxicity

Choi, D. W. (1987) · Journal of Neuroscience · doi:10.1523/jneurosci.07-02-00369.1987 · Cited by 1,854

Localization of neuronal and glial glutamate transporters

Rothstein, J. D., Martin, L. J., Levey, A. I., Dykes‐Hoberg, M., Jin, L., Wu, D. M., Nash, N. R., & Kuncl, R. W. (1994) · Neuron · doi:10.1016/0896-6273(94)90038-8 · Cited by 1,703

Glutamate uptake

Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227

Role of Glutamate and NMDA Receptors in Alzheimer’s Disease

Wang, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160763 · Cited by 1,009

Soluble Oligomers of Amyloid β Protein Facilitate Hippocampal Long-Term Depression by Disrupting Neuronal Glutamate Uptake

Li, S., Hong, S., Shepardson, N. E., Walsh, D. M., Shankar, G. M., & Selkoe, D. (2009) · Neuron · doi:10.1016/j.neuron.2009.05.012 · Cited by 972

Amyloid β-peptide (1-42)-induced Oxidative Stress and Neurotoxicity: Implications for Neurodegeneration in Alzheimer's Disease Brain. A Review

Allan Butterfield, D. (2002) · Free Radical Research · doi:10.1080/1071576021000049890 · Cited by 786

Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death1

Allanbutterfield, D., Castegna, A., Lauderback, C. M., & Drake, J. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00340-2 · Cited by 715

Astrocytes Maintain Glutamate Homeostasis in the CNS by Controlling the Balance between Glutamate Uptake and Release

Mahmoud, S., Gharagozloo, M., Simard, C., & Gris, D. (2019) · Cells · doi:10.3390/cells8020184 · Cited by 698

Function and therapeutic value of astrocytes in neurological diseases

Lee, H.-G., Wheeler, M. A., & Quintana, F. J. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00390-x · Cited by 662

A vicious cycle of β amyloid−dependent neuronal hyperactivation

Zott, B., Simon, M. M., Hong, W., Unger, F., Chen-Engerer, H.-J., Frosch, M. P., Sakmann, B., Walsh, D. M., & Konnerth, A. (2019) · Science · doi:10.1126/science.aay0198 · Cited by 640

The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention

Sheldon, A. L., & Robinson, M. B. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.03.012 · Cited by 593

Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part I: Creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1

Castegna, A., Aksenov, M., Aksenova, M., Thongboonkerd, V., Klein, J. B., Pierce, W. M., Booze, R., Markesbery, W. R., & Butterfield, D. A. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00914-0 · Cited by 581

Extrasynaptic NMDA Receptor Involvement in Central Nervous System Disorders

Parsons, M. P., & Raymond, L. A. (2014) · Neuron · doi:10.1016/j.neuron.2014.03.030 · Cited by 567

Oxidative stress in the brain: Novel cellular targets that govern survival during neurodegenerative disease

Chong, Z. Z., Li, F., & Maiese, K. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.02.004 · Cited by 536

Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration

Zwilling, D., Huang, S., Sathyasaikumar, K. V., Notarangelo, F. M., Guidetti, P., Wu, H., Lee, J. H., Truong, J. K., Andrews-Zwilling, Y. S., Hsieh, E., et al. (2011) · Cell · doi:10.1016/j.cell.2011.05.020 · Cited by 519

Synaptic degeneration in Alzheimer's disease

Arendt, T. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0536-x · Cited by 517

Alzheimer's disease, β‐amyloid, glutamate, NMDA receptors and memantine – searching for the connections

Danysz, W., & Parsons, C. G. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02057.x · Cited by 500

Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer’s disease

Kaur, D., Sharma, V., & Deshmukh, R. R. (2019) · Inflammopharmacology · doi:10.1007/s10787-019-00580-x · Cited by 503

Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury

Yi, J., & Hazell, A. S. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2005.12.001 · Cited by 477

The glial glutamate transporter, GLT‐1, is oxidatively modified by 4‐hydroxy‐2‐nonenal in the Alzheimer's disease brain: the role of Aβ1–42

Lauderback, C. M., Hackett, J. M., Huang, F. F., Keller, J. N., Szweda, L. I., Markesbery, W. R., & Butterfield, D. A. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00451.x · Cited by 464

Elusive roles for reactive astrocytes in neurodegenerative diseases

Ben Haim, L., Carrillo-de Sauvage, M.-A., Ceyzériat, K., & Escartin, C. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00278 · Cited by 453

Neurotransmitter Transporters in the Central Nervous System

Masson, J., Sagné, C., Hamon, M., & Mestikawy, S. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01414-5 · Cited by 413

Oxidative Stress, Amyloid-β Peptide, and Altered Key Molecular Pathways in the Pathogenesis and Progression of Alzheimer’s Disease

Butterfield, D. A., & Boyd-Kimball, D. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170543 · Cited by 403

The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence

Danysz, W., & Parsons, C. G. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.938 · Cited by 404

High Affinity Glutamate Transporters: Regulation of Expression and Activity

Gegelashvili, G., & Schousboe, A. (1997) · Molecular Pharmacology · doi:10.1124/mol.52.1.6 · Cited by 399

Prominent Axonopathy in the Brain and Spinal Cord of Transgenic Mice Overexpressing Four-Repeat Human tau Protein

Spittaels, K., den Haute, C. V., Dorpe, J. V., Bruynseels, K., Vandezande, K., Laenen, I., Geerts, H., Mercken, M. H., Sciot, R., Lommel, A. V., et al. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65533-2 · Cited by 390

Transporters for L ‐glutamate: An update on their molecular pharmacology and pathological involvement

Beart, P. M., & O’Shea, R. D. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706949 · Cited by 381

Glutamate transporters: animal models to neurologic disease

Maragakis, N. J., & Rothstein, J. D. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.007 · Cited by 362

Astrocytes: Role and Functions in Brain Pathologies

Siracusa, R., Fusco, R., & Cuzzocrea, S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01114 · Cited by 361

Astrocyte phenotype in relation to Alzheimer‐type pathology in the ageing brain

Simpson, J. E., Ince, P. G., Lace, G., Forster, G., Shaw, P. J., Matthews, F., Savva, G., Brayne, C., & Wharton, S. B. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.05.015 · Cited by 381

Glutamate Transporters in Neurologic Disease

Maragakis, N. J., & Rothstein, J. D. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.365 · Cited by 324

Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation

Behrens, P. F. (2002) · Brain · doi:10.1093/brain/awf180 · Cited by 322

Say NO to Alzheimer's disease: the putative links between nitric oxide and dementia of the Alzheimer's type

Law, A. (2001) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00051-5 · Cited by 314

Neuroinflammation in Alzheimer’s Disease

Onyango, I. G., Jauregui, G. V., Čarná, M., Bennett, J. P., & Stokin, G. B. (2021) · Biomedicines · doi:10.3390/biomedicines9050524 · Cited by 330

Glutamate system, amyloid β peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology

Revett, T. J., Baker, G. B., Jhamandas, J. H., & Kar, S. (2012) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.110190 · Cited by 308

Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice

Guo, H. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg267 · Cited by 297

The Glutamatergic System and Alzheimer???s Disease

Butterfield, D. A., & Pocernich, C. B. (2003) · CNS Drugs · doi:10.2165/00023210-200317090-00004 · Cited by 274

The critical role of methionine 35 in Alzheimer's amyloid β-peptide (1–42)-induced oxidative stress and neurotoxicity

Butterfield, D. A., & Debra Boyd-kimball, A. (2004) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2004.10.014 · Cited by 270

Molecular mechanisms of cognitive dysfunction following traumatic brain injury

Walker, K. R., & Tesco, G. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00029 · Cited by 265

Distribution of glutamate transporters in the hippocampus of patients with pharmaco‐resistant temporal lobe epilepsy

Proper, E. A., Hoogland, G., Kappen, S. M., Jansen, G. H., Rensen, M. G. A., Schrama, L. H., Veelen, C. W. M. V., van Rijen, P. C., van Nieuwenhuizen, O., Gispen, W. H., et al. (2002) · Brain · doi:10.1093/brain/awf001 · Cited by 264

Amyloid β‐Peptide(1‐42) Contributes to the Oxidative Stress and Neurodegeneration Found in Alzheimer Disease Brain

Butterfield, D. A., & Debra Boyd-kimball, A. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00087.x · Cited by 263

Protein Oxidation and Lipid Peroxidation in Brain of Subjects with Alzheimer's Disease: Insights into Mechanism of Neurodegeneration from Redox Proteomics

Rukhsana Sultana, A., Marzia Perluigi, A., & Butterfield, D. A. (2006) · Antioxidants and Redox Signaling · doi:10.1089/ars.2006.8.2021 · Cited by 261

Modulation of astrocyte reactivity improves functional deficits in mouse models of Alzheimer’s disease

Ceyzériat, K., Ben Haim, L., Denizot, A., Pommier, D., Matos, M., Guillemaud, O., Palomares, M.-A., Abjean, L., Petit, F., Gipchtein, P., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0606-1 · Cited by 256

Astrocyte energy and neurotransmitter metabolism in Alzheimer’s disease: Integration of the glutamate/GABA-glutamine cycle

Andersen, J. V., Schousboe, A., & Verkhratsky, A. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102331 · Cited by 263

Astrocyte dysfunction in Alzheimer disease

Acosta, C., Anderson, H. D., & Anderson, C. M. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24075 · Cited by 262

Antioxidants in Central Nervous System Diseases: Preclinical Promise and Translational Challenges

Kamat, C. D., Gadal, S., Mhatre, M., Williamson, K. S., Pye, Q. N., & Hensley, K. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15314 · Cited by 238

Targeting Neuroinflammation to Treat Alzheimer’s Disease

Ardura-Fabregat, A., Boddeke, E., Boza‐Serrano, A., Brioschi, S., Castro‐Gomez, S., Ceyzériat, K., Dansokho, C., Dierkes, T., Gelders, G., Heneka, M. T., et al. (2017) · CNS Drugs · doi:10.1007/s40263-017-0483-3 · Cited by 241

Glial transporters for glutamate, glycine and GABA I. Glutamate transporters

Gadea, A., & López-Colomé, A. M. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1039 · Cited by 227

Motor cortex excitability in Alzheimer's disease: A transcranial magnetic stimulation study

Ferreri, F., Pauri, F., Pasqualetti, P., Fini, R., Forno, G. D., & Rossini, P. M. (2002) · Annals of Neurology · doi:10.1002/ana.10416 · Cited by 223

Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: Involvement of oxidative stress and mitogen-activated protein kinase cascades

Matos, M., Augusto, E., Oliveira, C. R., & Agostinho, P. M. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.08.022 · Cited by 239

Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease

Takahashi, K., Foster, J. B., & Lin, C. G. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1937-8 · Cited by 227

Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain

Butterfield, D. A. (2004) · Brain Research · doi:10.1016/j.brainres.2003.12.012 · Cited by 210

d-glutamate and Gut Microbiota in Alzheimer’s Disease

Chang, C.-H., Lin, C.-H., & Lane, H.-Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082676 · Cited by 191

Carbonyl Toxicology and Alzheimer's Disease

Picklo, M. J. (2002) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2002.9506 · Cited by 194

Altered Glutamate Reuptake in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis Cortex: Correlation With Microglia Infiltration, Demyelination, and Neuronal and Synaptic Damage

Vercellino, M., Merola, A., Piacentino, C., Votta, B., Capello, E., Mancardi, G. L., Mutani, R., Giordana, M. T., & Cavalla, P. (2007) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31812571b0 · Cited by 190

The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain

Gąsiorowska, A., Wydrych, M., Drapich, P., Zadrożny, M., Steczkowska, M., Niewiadomski, W., & Niewiadomska, G. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.654931 · Cited by 199

Amyloid-β 1–42 Slows Clearance of Synaptically Released Glutamate by Mislocalizing Astrocytic GLT-1

Scimemi, A., Meabon, J. S., Woltjer, R. L., Sullivan, J. M., Diamond, J. S., & Cook, D. G. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.5274-12.2013 · Cited by 185

Memantine Improves Spatial Learning in a Transgenic Mouse Model of Alzheimer’s Disease

Minkeviciene, R., Banerjee, P., & Tanila, H. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.071027 · Cited by 187

Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease

Lane, R. M., & Farlow, M. R. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400486-jlr200 · Cited by 186

Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration

Butterfield, D. A., Debra Boyd-kimball, A., & Castegna, A. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01948.x · Cited by 183

Reactive astrocytes: The nexus of pathological and clinical hallmarks of Alzheimer’s disease

Price, B. R., Johnson, L. A., & Norris, C. M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101335 · Cited by 184

Environmental enrichment prevents astroglial pathological changes in the hippocampus of APP transgenic mice, model of Alzheimer's disease

Beauquis, J., Pavía, P., Pomilio, C., Vinuesa, A., Podlutskaya, N., Galvan, V., & Saravia, F. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.09.009 · Cited by 148

Amyloid β-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists

Butterfield, D. A., Griffin, S. T., Münch, G. W., & Pasinetti, G. M. (2002) · Journal of Alzheimer s Disease · doi:10.3233/jad-2002-4309 · Cited by 176

Glutamate–glutamine cycling in Alzheimer's disease

WALTON, H., & DODD, P. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2006.10.007 · Cited by 174

GluN2B subunit-containing NMDA receptor antagonists prevent Aβ-mediated synaptic plasticity disruption in vivo

Hu, N., Klyubin, I. V., Anwyl, R., & Rowan, M. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908083106 · Cited by 176

Excitatory Amino Acid Transporters in Physiology and Disorders of the Central Nervous System

Malik, A. R., & Willnow, T. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225671 · Cited by 170

Redox Proteomics in Selected Neurodegenerative Disorders: From Its Infancy to Future Applications

Butterfield, D. A., Marzia Perluigi, A., Reed, T. T., Muharib, T., Hughes, C. P., Robinson, R. A. S., & Rukhsana Sultana, A. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4109 · Cited by 171

The Regulation of Astrocytic Glutamate Transporters in Health and Neurodegenerative Diseases

Todd, A. C., & Hardingham, G. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249607 · Cited by 172

GLT-1 Loss Accelerates Cognitive Deficit Onset in an Alzheimer's Disease Animal Model

Mookherjee, P., Green, P. S., Watson, G. S., Marques, M. A., Tanaka, K., Meeker, K. D., Meabon, J. S., Li, N., Zhu, P., Olson, V. G., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110503 · Cited by 167

Reduced glutamine synthetase in hippocampal areas with neuron loss in temporal lobe epilepsy

van der Hel, W. S., Notenboom, R. G. E., Bos, I. W. M., van Rijen, P. C., Veelen, C. W. M. V., & Graan, P. N. E. D. (2005) · Neurology · doi:10.1212/01.wnl.0000149636.44660.99 · Cited by 166

Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid β-peptide (1–42) into rat brain: Implications for Alzheimer’s disease

Debra Boyd-kimball, A., Rukhsana Sultana, A., Poon, H. F., Lynn, B. C., Casamenti, F., Pepeu, G., Klein, J. B., & Butterfield, D. A. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2004.12.022 · Cited by 171

Glutamate transporter variants reduce glutamate uptake in Alzheimer's disease

Scott, H. A., Gebhardt, F. M., Mitrovic, A. D., Vandenberg, R. J., & Dodd, P. R. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.008 · Cited by 202

Role of By-Products of Lipid Oxidation in Alzheimer's Disease Brain: A Focus on Acrolein

Singh, M., Nam, D. T., Arseneault, M., & Ramassamy, C. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100405 · Cited by 162

Soluble Aβ oligomers impair hippocampal LTP by disrupting glutamatergic/GABAergic balance

Lei, M., Xu, H., Li, Z., Wang, Z., O’Malley, T. T., Zhang, D., Walsh, D. M., Xu, P., Selkoe, D. J., & Li, S. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.10.019 · Cited by 162

Regulation of oligodendrocyte differentiation: Protein kinase C activation prevents differentiation of O2A progenitor cells toward oligodendrocytes

Baron, W., de Jonge, J. C., Vries, H. D., & Hoekstra, D. (1998) · Glia · doi:10.1002/(sici)1098-1136(199802)22:2 · Cited by 56

Mapping synaptic glutamate transporter dysfunction in vivo to regions surrounding Aβ plaques by iGluSnFR two-photon imaging

Hefendehl, J. K., LeDue, J. M., Ko, R. W. Y., Mahler, J., Murphy, T. H., & MacVicar, B. A. (2016) · Nature Communications · doi:10.1038/ncomms13441 · Cited by 164

The solute carrier transporters and the brain: Physiological and pharmacological implications

Hu, C., Tao, L., Cao, X., & Chen, L. (2019) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2019.09.002 · Cited by 165

Restored glial glutamate transporter EAAT2 function as a potential therapeutic approach for Alzheimer’s disease

Takahashi, K., Kong, Q., Lin, Y., Stouffer, N., Schulte, D. A., Lai, L., Liu, Q., Chang, L., Dominguez, S., Xing, X., et al. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20140413 · Cited by 163

Activated astroglia during chronic inflammation in Alzheimer's disease--do they neglect their neurosupportive roles?

Fuller, S., Steele, M. L., & Münch, G. (2010) · Mutation research · doi:10.1016/j.mrfmmm.2009.08.016 · Cited by 164

Pyrrolidine Dithiocarbamate Activates Akt and Improves Spatial Learning in APP/PS1 Mice without Affecting β-Amyloid Burden

Malm, T., Iivonen, H., Goldsteins, G., Keksa-Goldsteine, V., Ahtoniemi, T., Kanninen, K. M., Salminen, A., Auriola, S. O. K., van Groen, T., Tanila, H., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0059-07.2007 · Cited by 157

Ceftriaxone ameliorates tau pathology and cognitive decline via restoration of glial glutamate transporter in a mouse model of Alzheimer's disease

Zumkehr, J., Rodríguez‐Ortiz, C. J., Cheng, D., Kieu, Z., Wai, T., Hawkins, C., Kilian, J., Lim, S., Medeiros, R., & Kitazawa, M. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.04.005 · Cited by 157

Astrocyte elevated gene-1: Recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration

Emdad, L., Sarkar, D., Su, Z.-Z., Lee, S., Kang, D., Bruce, J. N., Volsky, D. J., & Fisher, P. B. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.01.010 · Cited by 150

Advances in the Potential Biomarkers of Epilepsy

Kobylarek, D., Iwanowski, P. S., Lewandowska, Z., Limphaibool, N., Szafranek, S., Labrzycka, A., & Kozubski, W. P. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00685 · Cited by 157

Detrimental effects of chronic hypothalamic—pituitary—adrenal axis activation

Raber, J. (1998) · Molecular Neurobiology · doi:10.1007/bf02741457 · Cited by 154

Glutamate Transporter EAAT2: A New Target For The Treatment Of Neurodegenerative Diseases

Lin, C. G., Kong, Q., Cuny, G. D., & Glicksman, M. A. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.122 · Cited by 154

Brain excitability and connectivity of neuronal assemblies in Alzheimer's disease: From animal models to human findings

D’Amelio, M., & Rossini, P. M. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.07.001 · Cited by 147

Abnormal Glutamate Transport Function in Mutant Amyloid Precursor Protein Transgenic Mice

Masliah, E., Alford, M. F., Mallory, M. E., Rockenstein, E. M., Moechars, D., & LEUVEN, F. V. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7386 · Cited by 148

Estrogen and tamoxifen reverse manganese‐induced glutamate transporter impairment in astrocytes

Lee, E.-S., Sidoryk‐Wȩgrzynowicz, M., Jiang, H., Yin, Z., & Aschner, M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06105.x · Cited by 143

Proteomic identification of proteins oxidized by Aβ(1–42) in synaptosomes: Implications for Alzheimer's disease

Debra Boyd-kimball, A., Castegna, A., Rukhsana Sultana, A., Poon, H. F., Petroze, R. T., Lynn, B. C., Klein, J. B., & Butterfield, D. A. (2005) · Brain Research · doi:10.1016/j.brainres.2005.02.086 · Cited by 141

Effects of estrogen treatment on glutamate uptake in cultured human astrocytes derived from cortex of Alzheimer's disease patients

Liang, Z., Valla, J., Sefidvash-Hockley, S., Rogers, J., & Li, R. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2002.00779.x · Cited by 141

Chloride, carboxylate and carbonate transport by ortho-phenylenediamine-based bisureas

Moore, S. J., Haynes, C. J. E., González‐García, J., Sutton, J. L., Brooks, S. J., Light, M. E., Herniman, J., Langley, G. J., Soto‐Cerrato, V., Pérez‐Tomás, R., et al. (2012) · Chemical Science · doi:10.1039/c2sc21112b · Cited by 140

Pathological phenotypes of astrocytes in Alzheimer’s disease

Kim, J., Yoo, I. D., Lim, J., & Moon, J. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01148-0 · Cited by 154

Reactive astrocytes give neurons less support: implications for Alzheimer's disease

Steele, M. L., & Robinson, S. R. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.09.018 · Cited by 145

Overview of Glutamatergic Dysregulation in Central Pathologies

Miladinovic, T., Nashed, M. G., & Singh, G. (2015) · Biomolecules · doi:10.3390/biom5043112 · Cited by 145

Intracellular Calcium Dysregulation: Implications for Alzheimer’s Disease

Magi, S., Castaldo, P., Macrì, M. L., Maiolino, M., Matteucci, A., Bastioli, G., Gratteri, S., Amoroso, S., & Lariccia, V. (2016) · BioMed Research International · doi:10.1155/2016/6701324 · Cited by 151

Astrocytes in mouse models of tauopathies acquire early deficits and lose neurosupportive functions

Sidoryk‐Wȩgrzynowicz, M., Gerber, Y. N., Ries, M., Sastre, M., Tolkovsky, A. M., & Spillantini, M. G. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0478-9 · Cited by 137

Functional and structural damage of neurons by innate immune mechanisms during neurodegeneration

Ising, C., & Heneka, M. T. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0153-x · Cited by 140

Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease

Tikka, T., Vartiainen, N. E., Goldsteins, G., Oja, S. S., Andersen, P. M., Marklund, S. L., & Koıstınaho, J. (2002) · Brain · doi:10.1093/brain/awf068 · Cited by 136

Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: Implications for Aβ accumulation in AD brain

Owen, J. B., Rukhsana Sultana, A., Aluise, C. D., Erickson, M. A., Price, T. O., Bu, G., Banks, W. A., & Butterfield, D. A. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.09.013 · Cited by 132

The excitatory amino acid transporters: Pharmacological insights on substrate and inhibitor specificity of the EAAT subtypes

Bridges, R. J., & Esslinger, C. S. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.01.002 · Cited by 132

The 2013 SFRBM Discovery Award: Selected discoveries from the Butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment

Butterfield, D. A. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.06.006 · Cited by 126

Blood-brain barrier integrity in the pathogenesis of Alzheimer’s disease

Huang, Z., Wong, L., Su, Y., Huang, X., Wang, N., Chen, H., & Yi, C. (2020) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2020.100857 · Cited by 135

The glial glutamate transporter, GLT‐1, is oxidatively modified by 4‐hydroxy‐2‐nonenal in the Alzheimer's disease brain: the role of Aβ1–42

Lauderback, C. M., Hackett, J. M., Huang, F. F., Keller, J. N., Szweda, L. I., Markesbery, W. R., & Butterfield, D. A. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00451.x · Cited by 464

The Identification and Characterization of Excitotoxic Nerve-endings in Alzheimer Disease

Tannenberg, R. K., Scott, H. L., Westphalen, R. I., & Dodd, P. R. (2004) · Current Alzheimer Research · doi:10.2174/1567205043480591 · Cited by 37

Regional changes in [3H]d-aspartate and [3H]TCP binding sites in Alzheimer's disease brains

Simpson, M. D. C., Royston, M. C., Deakin, J. F. W., Cross, A. J., Mann, D. M. A., & Slater, P. (1988) · Brain Research · doi:10.1016/0006-8993(88)90587-2 · Cited by 74

Variant Forms of Neuronal Glutamate Transporter Sites in Alzheimer's Disease Cerebral Cortex

Scott, H. L., Tannenberg, A. E. G., & Dodd, P. R. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64052193.x · Cited by 74

P3–199: The glutamate transporter, EAAT3 (EAAC1), is aberrantly expressed in hippocampus of individuals with Alzheimer's disease

Cook, D. G., Deurson, K., Leverenz, J. B., Bird, T. D., Montine, T. J., & Pow, D. V. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.05.1467